Wide Applications of Glycan-Based Drugs to Drive Glycomic Therapeutics Market

According to our new research study on "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Class, Structures, Indications, and Mode of Action," the market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million by 2028; it is expected to grow at a CAGR of 15.8% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market. The wide application areas of glycan-based drugs, followed by the development of new treatment processes and increasing research & development in the field of glycomic therapeutics, are the key drivers propelling the market growth. However, the shortage of skilled professionals and lack of research & development laboratories in developing countries is hampering the overall market growth.

Glycomics focuses on the structures and functions of complex carbohydrates, as found in glycoproteins, glycolipids, and glycosaminoglycans. Glycans are responsible for much of the structural variation in biological systems, and their representation on cell surfaces is commonly called the "glycome". These glycans are present in many areas of the microbiome, including cell surfaces and proteins, and can be incredibly complex. Microbial glycomics is poised to revolutionize disease diagnosis, cancer detection, personalized medicine, antimicrobial vaccine, and drug discovery. As therapeutic agents, glycan-integrated nanomaterials can be used as a vaccine against viral and bacterial infections and cancer cells.

Wide Applications of Glycomics in Therapeutics

Glycomics is a novel method for creating medicines. It draws on the knowledge that glycans serve as the primary means of altering numerous molecules in biological systems. This alteration provides those molecules with their complete functional form. Glycans are found in most top-selling biologics and half of the therapeutic proteins, including antibodies against COVID-19. For instance, understanding the biological functions of glycans has led to their inclusion as essential ingredients in medications for the treatment of diabetes, the prevention of blood clotting, and the improvement of in vitro fertilization.

Changes in the glycans on a microbe's surface are frequently connected to the microorganisms' resistance to popular medications. This property is used for detecting particular glycans in infection samples, disabling the protective biofilms formed by the infecting bacteria, and weakening the glycan-rich cell walls of microorganisms.

Understanding that glycans are responsible for a few of these problems has helped develop therapies. Since glycans can play a crucial role in studying attacks of bacteria and viruses on the immune systems of humans, they are employed in vaccine development applications. Additionally, recent research on COVID-19 has shown infection pathways that depend on the virus's usage of human glycans.

Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomic in various therapeutic areas will propel the demand for genetic and proteomic techniques in the coming years. Moreover, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomic therapeutics market during the forecast period.

Intellihep Ltd; Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are among the leading companies operating in the glycomic therapeutics market.

Based on class, the glycomic therapeutics market is bifurcated into isolated and synthetic. Based on structures, the glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglcans, glycophosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. Based on indication, the glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anemia, anti-adhesive & anti-inflammatory, cataract, Gaucher's diseases, MPS-1 & IV, cancer, Alzheimer's disease, influenza type A & B, and others. Based on mode of action, the glycomic therapeutics market is segmented into inhibits neuraminidase; inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate; erythropoietin & enzyme replacement therapy (ERT); tissue plasminogen activator; inhibits glucosylceramide synthase; interleukin 1, 2 & 3; beta & gamma interferons; and others. By geography, the global glycomic therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com